Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
NACompletedINTERVENTIONAL
Enrollment
32
Participants
Timeline
Start Date
November 3, 2017
Primary Completion Date
January 31, 2020
Study Completion Date
January 31, 2020
Conditions
Schizophrenia
Interventions
DRUG
Placebo
Placebo
DRUG
Cannabidiol
Cannabidiol
Trial Locations (1)
Unknown
University Medical Center Utrecht, Utrecht
All Listed Sponsors
lead
UMC Utrecht
OTHER
NCT02932605 - Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia | Biotech Hunter | Biotech Hunter